Developer docs
API playgroundTry for free, no card

Search company profiles

Strata Oncology

Full company profile

uuid0000ru6

Namestring
Strata Oncology
Legal namestring
Strata Oncology, Inc.
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAnn Arbor, United States
HQ citystring
Ann Arbor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology diagnostics, molecular profiling services, cancer biomarker testing, immunotherapy predictive biomarkers, clinical genomic profiling
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Molecular Profiling Testing Services
TypeSubscription Recurring
Description

Strata Oncology generates revenue through clinical molecular profiling tests, including Strata Select, which provides treatment selection guidance for advanced cancer patients. Medicare coverage has been obtained for eligible beneficiaries. Revenue is derived from reimbursement from Medicare, commercial insurers, and potentially direct contracts with health systems.

strataoncology.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Strata Select test at $6,500 list charge, with Medicare coverage for qualifying patients
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

The No Surprises Act disclosure states a good-faith estimate of $6,500 for the Strata Select test based on the actual list charge. Medicare coverage is available for patients meeting specified coverage criteria. Financial assistance may reduce costs for qualifying patients.

strataoncology.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Strata Select
Description

A first-of-its-kind pan-solid tumor molecular profiling solution for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond.

strataoncology.com
+3 more records
Core offering1 text field

Strata Oncology is a precision oncology company that operates a CLIA-certified laboratory delivering Strata Select, a pan-solid tumor molecular profiling test combining DNA sequencing with quantitative RNA gene expression on a single small tumor tissue sample. The test incorporates proprietary multivariate biomarker algorithms—Immunotherapy Response Score (IRS) for predicting anti-PD-1/PD-L1 checkpoint inhibitor benefit and ADC Treatment Response Score (ADC TRS) for predicting antibody-drug conjugate response—to guide treatment selection for patients with advanced cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • IRS-H patients treated with pembrolizumab had median TTNT of 20.3 months vs 4.5 months on prior therapy (log-rank p<0.0001), while IRS-L patients had no benefit (3.3 vs 5.2 months, p=0.75)
+3 more records
Product overview1 text field

Strata Oncology offers a precision oncology platform centered on advanced algorithmic biomarkers. The core offering is Strata Select, a pan-solid tumor molecular profiling test launched in April 2023 that provides treatment selection guidance for immunotherapy and other treatments. Strata Select incorporates the Immunotherapy Response Score (IRS) for predicting anti-PD-1/PD-L1 benefit and also delivers ADC Treatment Response Score (ADC TRS) results. These proprietary biomarkers were developed using data from the Strata Trial observational clinical trial. The Strata PATH trial extends the platform to prospective interventional studies of FDA-approved therapies in biomarker-guided populations.

Product and service3 records
1Strata Select
CategoryMolecular Profiling Test / Precision Oncology Diagnostic
Description

A pan-solid tumor molecular profiling test for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond. Combines DNA sequencing with quantitative RNA gene expression on a single small tumor tissue sample, and includes the proprietary Immunotherapy Response Score (IRS) and ADC Treatment Response Score (ADC TRS) biomarker algorithms. Ordered by oncologists and cancer treatment centers from Strata Oncology's CLIA-certified laboratory; Medicare coverage available for qualifying beneficiaries at a $6,500 list charge.

2Immunotherapy Response Score (IRS)
CategoryPredictive Biomarker / Diagnostic Test
Description

A pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit. Combines tissue-based tumor mutation burden (TMB) with quantitative expression of PD-L1, PD-1, ADAM12, and TOP2A to identify which patients are likely to benefit from immunotherapy versus combination therapy. Delivered as part of Strata Select.

3ADC Treatment Response Score (ADC TRS)
CategoryPredictive Biomarker / Diagnostic Test
Description

A predictive biomarker for benefit from a variety of approved and investigational antibody-drug conjugates (ADCs). Based on a proprietary calculation method combining ADC target expression, proliferation, and adhesion as measured by RNAseq. Validated across multiple tumor types and ADC targets. Delivered as part of Strata Select and available to biopharma partners for ADC clinical trial patient selection.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kaiser Permanente Northern California conducted independent evaluations of Strata Oncology's Immunotherapy Response Score (IRS) using real-world patient data. KPNC oncologists, blinded to TRS status, determined best response to therapy from chart review. 211 KPNC patients from 24 solid tumor types were included in the pembrolizumab evaluation. 117 KPNC patients with bladder or breast cancer were evaluated for ADC TRS. This partnership generated peer-reviewed publications validating the biomarkers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Foundation Medicine (owned by Roche) offers FoundationOne CDx, a leading pan-solid tumor comprehensive genomic profiling test. Direct competitor to Strata Select in oncology molecular profiling and biomarker-driven clinical trial patient selection for pharma partners.

TypeBroad incumbent
Description

NeoGenomics is a larger oncology-focused clinical laboratory services company offering comprehensive molecular profiling, FISH, IHC, and cytogenetics tests. Overlaps with Strata in oncology testing services but is a much broader portfolio player.

TypeDirect peer
Description

Personalis offers NeXT Personal, a tumor-informed liquid biopsy and molecular profiling assay. Comparable in pan-solid tumor molecular profiling with both clinical and biopharma/biodefense customers, with overlapping DNA+RNA multi-omics approach.

TypeDirect peer
Description

Guardant Health provides liquid biopsy and molecular profiling for oncology, including Guardant360 for tumor profiling. Comparable in precision oncology diagnostics and biopharma CDx development, though Strata is tissue-based rather than blood-based.

TypeBroad incumbent
Description

Exact Sciences is a publicly-traded cancer diagnostics leader (Cologuard, Oncotype DX). While primarily known for colorectal screening and breast cancer recurrence testing, it competes in precision oncology decision support and biomarker-driven testing.

TypeEmerging player
Description

Adaptive Biotechnologies offers clonoSEQ (MRD) and immune profiling assays. Comparable in molecular diagnostics for oncology treatment monitoring with biopharma partnership model, though focused on immuno-sequencing rather than tumor profiling.

TypeDirect peer
Description

Caris offers MI Profile (DNA/RNA molecular profiling) and Caris Assure (liquid biopsy) for oncology treatment selection. Closely comparable to Strata in molecular profiling services and biopharma companion-diagnostic partnerships.

8Tempus AI
TypeDirect peer
Description

Tempus provides AI-enabled precision medicine including its xT and xR oncology assays covering DNA/RNA sequencing for solid tumors. Directly comparable to Strata in pan-solid tumor profiling for both oncologist ordering and biopharma partnerships.

TypeBroad incumbent
Description

Resolution Bioscience, acquired by Agilent, offers liquid biopsy NGS for oncology. Overlaps with Strata in oncology molecular profiling and biopharma CDx development but operates within a much larger life sciences tools parent.

TypeBroad incumbent
Description

Natera offers Signatera (tumor-informed MRD) and other oncology molecular tests. Comparable in molecular diagnostics and biopharma partnerships, with broader presence in reproductive testing as well.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Strata Oncology

Precision Oncology Diagnosticsstrataoncology.com

Strata Oncology firmographics

Firmographics
Name
Strata Oncology
Legal name
Strata Oncology, Inc.
Website
https://strataoncology.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Strata Oncology industry classification

Industry
Product category
Precision Oncology Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)

Keywords

  • Precision oncology diagnostics
  • Molecular profiling services
  • Cancer biomarker testing
  • Immunotherapy predictive biomarkers
  • Clinical genomic profiling

Where Strata Oncology is headquartered

Location

Headquarters

HQ city
Ann Arbor
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Strata Oncology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Molecular Profiling Testing Services: Strata Oncology generates revenue through clinical molecular profiling tests, including Strata Select, which provides treatment selection guidance for advanced cancer patients. Medicare coverage has been obtained for eligible beneficiaries. Revenue is derived from reimbursement from Medicare, commercial insurers, and potentially direct contracts with health systems.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goStrata Select test at $6,500 list charge, with Medicare coverage for qualifying patients

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Strata Oncology product offering

Product offering

Core offering

Strata Oncology is a precision oncology company that operates a CLIA-certified laboratory delivering Strata Select, a pan-solid tumor molecular profiling test combining DNA sequencing with quantitative RNA gene expression on a single small tumor tissue sample. The test incorporates proprietary multivariate biomarker algorithms—Immunotherapy Response Score (IRS) for predicting anti-PD-1/PD-L1 checkpoint inhibitor benefit and ADC Treatment Response Score (ADC TRS) for predicting antibody-drug conjugate response—to guide treatment selection for patients with advanced cancer.

Product overview

Strata Oncology offers a precision oncology platform centered on advanced algorithmic biomarkers. The core offering is Strata Select, a pan-solid tumor molecular profiling test launched in April 2023 that provides treatment selection guidance for immunotherapy and other treatments. Strata Select incorporates the Immunotherapy Response Score (IRS) for predicting anti-PD-1/PD-L1 benefit and also delivers ADC Treatment Response Score (ADC TRS) results. These proprietary biomarkers were developed using data from the Strata Trial observational clinical trial. The Strata PATH trial extends the platform to prospective interventional studies of FDA-approved therapies in biomarker-guided populations.

Differentiator

Problem solved

Functional benefit

Brands

  • Strata Select: A first-of-its-kind pan-solid tumor molecular profiling solution for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond.
  • Immunotherapy Response Score (IRS)
  • ADC Treatment Response Score (ADC TRS)
  • Strata Trial

Products and services

  • Strata Select A pan-solid tumor molecular profiling test for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond. Combines DNA sequencing with quantitative RNA gene expression on a single small tumor tissue sample, and includes the proprietary Immunotherapy Response Score (IRS) and ADC Treatment Response Score (ADC TRS) biomarker algorithms. Ordered by oncologists and cancer treatment centers from Strata Oncology's CLIA-certified laboratory; Medicare coverage available for qualifying beneficiaries at a $6,500 list charge.
  • Immunotherapy Response Score (IRS) A pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit. Combines tissue-based tumor mutation burden (TMB) with quantitative expression of PD-L1, PD-1, ADAM12, and TOP2A to identify which patients are likely to benefit from immunotherapy versus combination therapy. Delivered as part of Strata Select.
  • ADC Treatment Response Score (ADC TRS) A predictive biomarker for benefit from a variety of approved and investigational antibody-drug conjugates (ADCs). Based on a proprietary calculation method combining ADC target expression, proliferation, and adhesion as measured by RNAseq. Validated across multiple tumor types and ADC targets. Delivered as part of Strata Select and available to biopharma partners for ADC clinical trial patient selection.

Quantifiable outcome

  • IRS-H patients treated with pembrolizumab had median TTNT of 20.3 months vs 4.5 months on prior therapy (log-rank p<0.0001), while IRS-L patients had no benefit (3.3 vs 5.2 months, p=0.75)
  • +3 more outcomes

Companies that use Strata Oncology

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Strata Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Strata Oncology partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kaiser Permanente Northern CaliforniacoreStrategic or Co-development PartnerKaiser Permanente Northern California conducted independent evaluations of Strata Oncology's Immunotherapy Response Score (IRS) using real-world patient data. KPNC oncologists, blinded to TRS status, determined best response to therapy from chart review. 211 KPNC patients from 24 solid tumor types were included in the pembrolizumab evaluation. 117 KPNC patients with bladder or breast cancer were evaluated for ADC TRS. This partnership generated peer-reviewed publications validating the biomarkers.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Strata Oncology competitors and assessment

Company assessment

Direct peers

  • Foundation Medicine: Foundation Medicine (owned by Roche) offers FoundationOne CDx, a leading pan-solid tumor comprehensive genomic profiling test. Direct competitor to Strata Select in oncology molecular profiling and biomarker-driven clinical trial patient selection for pharma partners.
  • Personalis: Personalis offers NeXT Personal, a tumor-informed liquid biopsy and molecular profiling assay. Comparable in pan-solid tumor molecular profiling with both clinical and biopharma/biodefense customers, with overlapping DNA+RNA multi-omics approach.
  • Guardant Health: Guardant Health provides liquid biopsy and molecular profiling for oncology, including Guardant360 for tumor profiling. Comparable in precision oncology diagnostics and biopharma CDx development, though Strata is tissue-based rather than blood-based.
  • Caris Life Sciences: Caris offers MI Profile (DNA/RNA molecular profiling) and Caris Assure (liquid biopsy) for oncology treatment selection. Closely comparable to Strata in molecular profiling services and biopharma companion-diagnostic partnerships.
  • Tempus AI: Tempus provides AI-enabled precision medicine including its xT and xR oncology assays covering DNA/RNA sequencing for solid tumors. Directly comparable to Strata in pan-solid tumor profiling for both oncologist ordering and biopharma partnerships.

Broad incumbents

  • NeoGenomics: NeoGenomics is a larger oncology-focused clinical laboratory services company offering comprehensive molecular profiling, FISH, IHC, and cytogenetics tests. Overlaps with Strata in oncology testing services but is a much broader portfolio player.
  • Exact Sciences: Exact Sciences is a publicly-traded cancer diagnostics leader (Cologuard, Oncotype DX). While primarily known for colorectal screening and breast cancer recurrence testing, it competes in precision oncology decision support and biomarker-driven testing.
  • Resolution Bioscience (Agilent): Resolution Bioscience, acquired by Agilent, offers liquid biopsy NGS for oncology. Overlaps with Strata in oncology molecular profiling and biopharma CDx development but operates within a much larger life sciences tools parent.
  • Natera: Natera offers Signatera (tumor-informed MRD) and other oncology molecular tests. Comparable in molecular diagnostics and biopharma partnerships, with broader presence in reproductive testing as well.

Emerging players

  • Adaptive Biotechnologies: Adaptive Biotechnologies offers clonoSEQ (MRD) and immune profiling assays. Comparable in molecular diagnostics for oncology treatment monitoring with biopharma partnership model, though focused on immuno-sequencing rather than tumor profiling.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Strata Oncology social profiles

Digital presence

Strata Oncology compliance and trust

Trust signal

Compliance1 record

Strata Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Strata Oncology leadership team

Management profile

Number of profiles

Profiles14 records

Strata Oncology funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Strata Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strata Oncology

What does Strata Oncology do?

Strata Oncology is a precision oncology company that operates a CLIA-certified laboratory delivering Strata Select, a pan-solid tumor molecular profiling test combining DNA sequencing with quantitative RNA gene expression on a single small tumor tissue sample. The test incorporates proprietary multivariate biomarker algorithms—Immunotherapy Response Score (IRS) for predicting anti-PD-1/PD-L1 checkpoint inhibitor benefit and ADC Treatment Response Score (ADC TRS) for predicting antibody-drug conjugate response—to guide treatment selection for patients with advanced cancer.

Is Strata Oncology a public or private company?

Strata Oncology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Strata Oncology founded?

Strata Oncology was founded in 2016. It employs 11 to 50 people.

Where is Strata Oncology based?

Strata Oncology is headquartered in Ann Arbor, United States, in the North America region.

How does Strata Oncology make money?

One revenue line is on record: molecular Profiling Testing Services.

Who are Strata Oncology's main competitors?

Direct peers on record are Foundation Medicine, Personalis, Guardant Health, Caris Life Sciences and Tempus AI. Broad incumbents are NeoGenomics, Exact Sciences, Resolution Bioscience (Agilent) and Natera. Adaptive Biotechnologies is listed as an emerging player.

Does Strata Oncology have an API?

No public API is recorded for Strata Oncology.

What industry is Strata Oncology in?

Strata Oncology's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogStrata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough AwardsStrata Oncology won the "Diagnostics Innovation Of The Year" award from BioTech Breakthrough Awards for its Strata Select platform. The platform provides treatment selection guidance for immunotherapy using the Immunotherapy Response Score, validated in multiple publications. The company aims to help patients and doctors make confident treatment decisions.Clinical Lab ProductsHow Clinical Diagnostics Will Drive Precision MedicineStrata Oncology's CEO Dan Rhodes discusses how clinical diagnostics, particularly its Strata Select test, will drive precision medicine. The test combines DNA and RNA sequencing to predict immunotherapy response and is the first to receive Medicare reimbursement. Rhodes expects tumor testing to become standard of care within five to ten years.PR NewswireStrata Oncology Announces Appointment of Goz Alhir as Senior Vice President of CommercializationStrata Oncology appointed Goz Alhir as Senior Vice President of Commercialization to lead market strategy and growth for its precision oncology products. This executive hire aims to expand patient access to Strata Select by leveraging Alhir's extensive experience in healthcare leadership and sales across the oncology ecosystem.PR NewswireStrata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung CancerStrata Oncology announced new data at the 2023 World Conference on Lung Cancer showing its Immunotherapy Response Score (IRS) biomarker algorithm can support informed clinical decisions for first-line treatment of non-small cell lung cancer patients beyond standard PD-L1 testing. A pre-specified analysis of over 200 NSCLC patients from Kaiser Permanente Northern California treated with pembrolizumab alone or with chemotherapy demonstrated that IRS was significantly associated with time-to-next-treatment independent of therapy type and PD-L1 status. Among patients with PD-L1 High tumors, IRS High patients showed significantly longer time-to-next-treatment on single-agent pembrolizumab compared to IRS Low patients, indicating IRS could guide selection between pembrolizumab monotherapy and combination chemotherapy.PR NewswireStrata Oncology Receives Honorable Mention in Fast Company's 2023 World Changing Ideas AwardsStrata Oncology received an honorable mention in Fast Company's 2023 World Changing Ideas Awards for its Immunotherapy Response Score, a predictive biomarker algorithm for checkpoint inhibitor immunotherapy, marking the second consecutive year the company has been recognized by this awards program. The company also recently secured Medicare coverage for its Strata Select pan-solid tumor molecular profiling test, which incorporates the Immunotherapy Response Score. The CEO credited the recognition as validation of Strata Oncology's commitment to advancing precision oncology and improving patient outcomes.PR NewswireStrata Oncology Announces Publication of Study Validating Clinical Utility of Pan-tumor Predictive Biomarker for Checkpoint Inhibitor Immunotherapy BenefitStrata Oncology announced the publication of a peer-reviewed study in Communications Medicine validating their Immunotherapy Response Score (IRS), a pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit. The study found that IRS-high status identified twice as many patients who may benefit from checkpoint inhibitor treatment compared to tumor mutational burden (TMB), and in non-small cell lung cancer patients, IRS-high status showed no significant benefit of combination therapy (pembrolizumab + chemotherapy) over monotherapy (pembrolizumab). The company aims to expand immunotherapy benefit to more patients and help physicians optimize treatment selection using this diagnostic tool.PR NewswireStrata Oncology Announces Addition of Gilead as Strata PATH Trial CollaboratorStrata Oncology announced that Gilead Sciences has agreed to collaborate on the Strata PATH trial by providing TRODELVY (Sacituzumab govitecan-hziy) for eligible cancer patients. The Strata PATH trial is a 700-patient prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations using quantitative RNA and multivariate algorithms. This collaboration brings together two precision oncology companies to potentially expand treatment options for cancer patients.PR NewswireStrata Oncology Expands Sentinel Trial with Lehigh Valley Topper Cancer Institute and University of Michigan Health Rogel Cancer Center to Bring Precision Therapies to Patients Earlier in Their CancerStrata Oncology announced that Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center have joined as clinical trial sites in the Strata Sentinel trial, a prospective observational study evaluating the StrataMRD minimal residual disease test for cancer recurrence detection. The approximately 100,000-patient trial across 25 sites is the largest of its kind, using ctDNA-based blood testing to detect cancer recurrence earlier than standard care and guide treatment decisions with biomarker-matched therapies. All molecular profiling will be conducted at Strata Oncology's CAP-accredited and CLIA-certified laboratory in Ann Arbor, Michigan.PR NewswireStrata Oncology Receives Honorable Mention in the Health Category of Fast Company's 2022 World Changing Ideas AwardsStrata Oncology received an honorable mention in the health category of Fast Company's 2022 World Changing Ideas Awards for its Strata PATH clinical trial, a prospective pan-tumor therapeutic trial evaluating FDA-approved cancer therapies in new biomarker-guided patient populations. The Strata PATH trial leverages proprietary quantitative RNA algorithms developed using a clinical molecular database tied to real-world outcomes from tens of thousands of patients. Now in its sixth year, the World Changing Ideas Awards selected winners and finalists from over 2,997 entries across transportation, education, food, politics, technology, health, social justice, and more.PR NewswireStrata Oncology Sentinel Trial for Personalized Cancer Recurrence Monitoring Enrolls First PatientStrata Oncology announced enrollment of the first patient in the Strata Sentinel trial, a prospective observational study evaluating the investigational StrataMRD test for detecting cancer recurrence through tumor-informed ctDNA-based minimal residual disease (MRD) testing across solid tumors. The trial will enroll approximately 100,000 patients with stage 1-3 solid tumors across 25 sites over five years, making it the largest study of its kind to date. If recurrence is detected, treating physicians can use comprehensive therapy selection profiling to guide treatment decisions, including potential enrollment in the Strata PATH clinical trial.